Pfizer Inc. (NYSE: PFE) is a research-based global biopharmaceutical company navigating a period of post-pandemic revenue normalization, as COVID-19 vaccine and antiviral sales decline sharply from their 2022 peak, while the company works to grow its non-COVID business through core therapeutic areas and the 2023 acquisition of Seagen in oncology. This page brings together live PFE market data, charting, financials, technical indicators, company details, recent news and a clearly labelled Shariah-screening snapshot for research purposes. Market data and widgets below update dynamically; Shariah status should be treated as time-sensitive and independently verified.
Key Investor Considerations for Pfizer
Potential Strengths
- Broad, diversified pipeline across oncology, vaccines, internal medicine, inflammation/immunology and rare disease
- Expanded oncology franchise following the 2023 Seagen acquisition, including antibody-drug-conjugate products such as Padcev
- Continued dividend payments through the post-pandemic revenue normalization period, with an elevated dividend yield reflecting the stock’s price decline
- Cost-reduction and productivity programs aimed at offsetting COVID-related revenue decline
- Large-scale manufacturing and commercial infrastructure built up through the COVID-19 vaccine rollout
- Continued investment in R&D across multiple modalities and therapeutic areas
Material Risks
- COVID-19 product revenue (Comirnaty and Paxlovid) has declined substantially from 2022 peak levels and continues to be a source of guidance uncertainty
- Loss-of-exclusivity risk facing several major products over the coming years
- Integration risk and return-on-investment scrutiny tied to the Seagen acquisition and other recent deal activity
- Clinical and regulatory failure risk inherent to early- and late-stage pipeline assets
- Intense competition from Merck, Johnson & Johnson, AbbVie, Bristol Myers Squibb and other large biopharmaceutical companies
- Drug-pricing and regulatory reform exposure affecting U.S. and international markets
Frequently Asked Questions
What does Pfizer Inc. do?
Pfizer is a research-based global biopharmaceutical company that discovers, develops, manufactures and sells medicines and vaccines across therapeutic areas including oncology, vaccines, internal medicine, inflammation and immunology, and rare disease.
On which exchange is Pfizer listed?
Pfizer Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol PFE.
Why has Pfizer’s revenue declined since 2022?
Pfizer’s 2022 revenue peaked due to exceptionally high sales of its COVID-19 vaccine (Comirnaty) and antiviral (Paxlovid). As pandemic-driven demand for these products normalized, COVID-related revenue declined substantially, and Pfizer has since focused on growing its non-COVID and oncology business to offset that decline.
What was the Seagen acquisition?
Pfizer completed its acquisition of Seagen in 2023, adding an antibody-drug-conjugate oncology pipeline and products such as Padcev, aimed at strengthening Pfizer’s oncology franchise and diversifying revenue away from COVID-related products.
Does Pfizer pay a dividend?
Yes. Pfizer has continued to pay and modestly increase its dividend through its post-pandemic revenue normalization, resulting in a dividend yield that is elevated relative to historical norms due to the stock’s price decline. Investors should verify the current payout through Pfizer’s investor relations page before relying on it.
Who are Pfizer’s main competitors?
Pfizer competes with Merck, Johnson & Johnson, AbbVie and Bristol Myers Squibb across its core therapeutic areas, and with Moderna in vaccines.
Is Pfizer stock currently Shariah compliant?
Zoya screens PFE as NOT Shariah-compliant under AAOIFI standards, despite a relatively low disclosed interest-income ratio of approximately 0.96% of combined revenue. This page checked only Zoya as a screening source; investors should confirm current status through a named provider or qualified Shariah adviser before relying on it.
Conclusion
Pfizer is navigating a period of post-pandemic revenue normalization, as COVID-19 vaccine and antiviral sales continue to decline from their 2022 peak, while the company works to rebuild its growth profile through its core therapeutic areas and the 2023 Seagen acquisition, which expanded its oncology pipeline. That position is balanced against continued COVID-product revenue uncertainty, loss-of-exclusivity risk facing several major products, and intense competition from Merck, Johnson & Johnson, AbbVie and other large biopharmaceutical companies. The tools on this page — charts, financials, technical indicators and news — support ongoing research into Pfizer’s position, but they do not replace a review of Pfizer’s official filings or independent financial, legal, tax or Shariah advice.